Limits...
Integrated Treatment of Aqueous Extract of Solanum nigrum-Potentiated Cisplatin- and Doxorubicin-Induced Cytotoxicity in Human Hepatocellular Carcinoma Cells.

Wang CK, Lin YF, Tai CJ, Wang CW, Chang YJ, Choong CY, Lin CS, Tai CJ, Chang CC - Evid Based Complement Alternat Med (2015)

Bottom Line: Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5.The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells.In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Department of Chinese Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.

ABSTRACT
Chemotherapy is the main approach for treating advanced and recurrent hepatocellular carcinoma (HCC), but the clinical performance of chemotherapy is limited by a relatively low response rate, drug resistance, and adverse effects that severely affect the quality of life of patients. The aqueous extract of Solanum nigrum (AE-SN) is a crucial ingredient in some traditional Chinese medicine (TCM) formulas for treating cancer patients and exhibits antitumor effects in human HCC cells. Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5. The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells. In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

No MeSH data available.


Related in: MedlinePlus

AE-SN treatment inhibited Hep3B and HepJ5 cell growth. (a) Hep3B and HepJ5 cells were treated with 0.1 to 2 mg/mL of AE-SN for 48 h, and the cell viability was determined using an MTT assay. The data are presented as the mean ± standard deviation. (b) Hep3B and HepJ5 cells were treated with 1.0 mg/mL of AE-SN for 48 h, and the cell size distribution was determined according to the cell diameter by using a Scepter cell counter. Arrows indicate a cell diameter of 12 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499398&req=5

fig2: AE-SN treatment inhibited Hep3B and HepJ5 cell growth. (a) Hep3B and HepJ5 cells were treated with 0.1 to 2 mg/mL of AE-SN for 48 h, and the cell viability was determined using an MTT assay. The data are presented as the mean ± standard deviation. (b) Hep3B and HepJ5 cells were treated with 1.0 mg/mL of AE-SN for 48 h, and the cell size distribution was determined according to the cell diameter by using a Scepter cell counter. Arrows indicate a cell diameter of 12 μm.

Mentions: In this study, 48 h treatment with 0 to 2.0 mg/mL of AE-SN gradually inhibited the growth of Hep3B and HepJ5 cells in a concentration-dependent manner (one-way ANOVA, P < 0.01, Figure 2(a)). The IC50 values of AE-SN for the Hep3B and HepJ5 cells were 0.96 and 0.97 mg/mL, respectively. AE-SN treatment also resulted in the production of cell fragments and debris, which were less than 12 μm in diameter in comparison with cells treated with the control medium in both Hep3B and HepJ5 cells (Figure 2(b)). Collectively, these results suggested that AE-SN inhibited cell growth and demonstrated cytotoxicity in Hep3B and HepJ5 cells.


Integrated Treatment of Aqueous Extract of Solanum nigrum-Potentiated Cisplatin- and Doxorubicin-Induced Cytotoxicity in Human Hepatocellular Carcinoma Cells.

Wang CK, Lin YF, Tai CJ, Wang CW, Chang YJ, Choong CY, Lin CS, Tai CJ, Chang CC - Evid Based Complement Alternat Med (2015)

AE-SN treatment inhibited Hep3B and HepJ5 cell growth. (a) Hep3B and HepJ5 cells were treated with 0.1 to 2 mg/mL of AE-SN for 48 h, and the cell viability was determined using an MTT assay. The data are presented as the mean ± standard deviation. (b) Hep3B and HepJ5 cells were treated with 1.0 mg/mL of AE-SN for 48 h, and the cell size distribution was determined according to the cell diameter by using a Scepter cell counter. Arrows indicate a cell diameter of 12 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499398&req=5

fig2: AE-SN treatment inhibited Hep3B and HepJ5 cell growth. (a) Hep3B and HepJ5 cells were treated with 0.1 to 2 mg/mL of AE-SN for 48 h, and the cell viability was determined using an MTT assay. The data are presented as the mean ± standard deviation. (b) Hep3B and HepJ5 cells were treated with 1.0 mg/mL of AE-SN for 48 h, and the cell size distribution was determined according to the cell diameter by using a Scepter cell counter. Arrows indicate a cell diameter of 12 μm.
Mentions: In this study, 48 h treatment with 0 to 2.0 mg/mL of AE-SN gradually inhibited the growth of Hep3B and HepJ5 cells in a concentration-dependent manner (one-way ANOVA, P < 0.01, Figure 2(a)). The IC50 values of AE-SN for the Hep3B and HepJ5 cells were 0.96 and 0.97 mg/mL, respectively. AE-SN treatment also resulted in the production of cell fragments and debris, which were less than 12 μm in diameter in comparison with cells treated with the control medium in both Hep3B and HepJ5 cells (Figure 2(b)). Collectively, these results suggested that AE-SN inhibited cell growth and demonstrated cytotoxicity in Hep3B and HepJ5 cells.

Bottom Line: Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5.The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells.In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan ; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan ; Department of Chinese Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.

ABSTRACT
Chemotherapy is the main approach for treating advanced and recurrent hepatocellular carcinoma (HCC), but the clinical performance of chemotherapy is limited by a relatively low response rate, drug resistance, and adverse effects that severely affect the quality of life of patients. The aqueous extract of Solanum nigrum (AE-SN) is a crucial ingredient in some traditional Chinese medicine (TCM) formulas for treating cancer patients and exhibits antitumor effects in human HCC cells. Therefore, this study examined the tumor-suppression efficiency of AE-SN integrated with a standard chemotherapeutic drug, namely, cisplatin or doxorubicin, in human HCC cells, namely, Hep3B and HepJ5. The results suggested that the integrated treatment with AE-SN-potentiated cisplatin and doxorubicin induced cytotoxicity through the cleavage of caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3 A/B II), which were associated with apoptotic and autophagic cell death, respectively, in both the Hep3B and HepJ5 cells. In conclusion, AE-SN can potentially be used in novel integrated chemotherapy with cisplatin or doxorubicin to treat HCC patients.

No MeSH data available.


Related in: MedlinePlus